Who
Hans T. Schambye
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Galecto.
In numbers
- Trades disclosed
- 25
- Buys
- 3
- Sells
- 3
- Bought
- $42K
- Sold
- $40K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 Jun 2020
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | GalectoBiotechnology | SEC FORM 4 Code M | —1,360 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GalectoBiotechnology | SEC FORM 4 Sold | $15K700 at $21.38 | filing |
| 2 Jan 2026filed 6 Jan 2026 | Galectooption or derivative · Biotechnology | SEC FORM 4 Code M | —1,360 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,360 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,360 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K700 at $21.38 | filing |
| 3 Jul 2025filed 8 Jul 2025 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,360 at $0.00 | filing |
| 3 Jul 2025filed 8 Jul 2025 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,360 | filing |
| 3 Jul 2025filed 8 Jul 2025 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,484735 at $3.38 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,640 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,400 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,640 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,5101,341 at $5.60 | filing |
| 9 Oct 2024filed 11 Oct 2024 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,100 at $0.00 | filing |
| 3 Jan 2024filed 5 Jan 2024 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 4 Jan 2023filed 5 Jan 2023 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 22 Mar 2022filed 23 Mar 2022 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K5,000 at $2.15 | filing |
| 4 Jan 2022filed 6 Jan 2022 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —287,500 at $0.00 | filing |
| 9 Nov 2021filed 10 Nov 2021 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Bought | $16K4,500 at $3.50 | filing |
| 24 Jun 2021filed 24 Jun 2021 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K3,000 at $5.11 | filing |
News
No headline names them, or the companies they trade most, lately.